Morgan Stanley’s Cardlytics CDLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $297 | Buy |
66
+3
| +5% | +$22 | ﹤0.01% | 7788 |
|
|
2026
Q1 | $657 | Sell |
63
-310
| -83% | -$3.02K | ﹤0.01% | 7575 |
|
|
2025
Q4 | $4.29K | Sell |
373
-48,439
| -99% | -$748K | ﹤0.01% | 7099 |
|
|
2025
Q3 | $1.19M | Buy |
48,812
+16,266
| +50% | +$271K | ﹤0.01% | 5092 |
|
|
2025
Q2 | $535K | Buy |
32,546
+3,590
| +12% | +$62K | ﹤0.01% | 5434 |
|
|
2025
Q1 | $527K | Sell |
28,956
-10,022
| -26% | -$286K | ﹤0.01% | 5304 |
|
|
2024
Q4 | $1.45M | Buy |
38,978
+3,366
| +9% | +$129K | ﹤0.01% | 4902 |
|
|
2024
Q3 | $1.14M | Sell |
35,612
-180,981
| -84% | -$10M | ﹤0.01% | 4980 |
|
|
2024
Q2 | $17.8M | Sell |
216,593
-12,381
| -5% | -$1.34M | ﹤0.01% | 2795 |
|
|
2024
Q1 | $33.2M | Buy |
228,974
+117,672
| +106% | +$9.94M | ﹤0.01% | 2150 |
|
|
2023
Q4 | $10.3M | Buy |
111,302
+39,148
| +54% | +$3.98M | ﹤0.01% | 3324 |
|
|
2023
Q3 | $11.9M | Buy |
72,154
+36,128
| +100% | +$4.69M | ﹤0.01% | 2962 |
|
|
2023
Q2 | $2.28M | Sell |
36,026
-4,577
| -11% | -$277K | ﹤0.01% | 4346 |
|
|
2023
Q1 | $1.38M | Sell |
40,603
-6,411
| -14% | -$335K | ﹤0.01% | 4681 |
|
|
2022
Q4 | $2.72M | Buy |
47,014
+25,235
| +116% | +$1.56M | ﹤0.01% | 4251 |
|
|
2022
Q3 | $2.05M | Sell |
21,779
-45,518
| -68% | -$6.48M | ﹤0.01% | 4415 |
|
|
2022
Q2 | $15M | Sell |
67,297
-9,748
| -13% | -$3.26M | ﹤0.01% | 2601 |
|
|
2022
Q1 | $42.4M | Sell |
77,045
-17,388
| -18% | -$10.5M | 0.01% | 1417 |
|
|
2021
Q4 | $62.4M | Buy |
94,433
+977
| +1% | +$747K | 0.01% | 1191 |
|
|
2021
Q3 | $78.4M | Buy |
93,456
+18,127
| +24% | +$18.4M | 0.01% | 979 |
|
|
2021
Q2 | $95.6M | Sell |
75,329
-28,077
| -27% | -$31.7M | 0.01% | 872 |
|
|
2021
Q1 | $113M | Buy |
103,406
+21,121
| +26% | +$27.9M | 0.02% | 698 |
|
|
2020
Q4 | $117M | Sell |
82,285
-3,968
| -5% | -$4.23M | 0.02% | 648 |
|
|
2020
Q3 | $60.9M | Buy |
86,253
+9,935
| +13% | +$7.22M | 0.01% | 812 |
|
|
2020
Q2 | $53.4M | Buy |
76,318
+45,470
| +147% | +$26.3M | 0.01% | 813 |
|
|
2020
Q1 | $10.8M | Sell |
30,848
-9,715
| -24% | -$6.88M | ﹤0.01% | 1708 |
|
|
2019
Q4 | $25.5M | Buy |
40,563
+17,386
| +75% | +$8.5M | 0.01% | 1447 |
|
|
2019
Q3 | $7.77M | Buy |
23,177
+21,859
| +1,658% | +$7.01M | ﹤0.01% | 2385 |
|
|
2019
Q2 | $342K | Buy |
1,318
+1,165
| +761% | +$233K | ﹤0.01% | 4788 |
|
|
2019
Q1 | $25K | Sell |
153
-3,056
| -95% | -$497K | ﹤0.01% | 5937 |
|
|
2018
Q4 | $348K | Buy |
3,209
+1,620
| +102% | +$273K | ﹤0.01% | 5024 |
|
|
2018
Q3 | $398K | Buy |
1,589
+335
| +27% | +$72.1K | ﹤0.01% | 5122 |
|
|
2018
Q2 | $273K | Buy |
1,254
+66
| +6% | +$12.2K | ﹤0.01% | 5413 |
|
|
2018
Q1 | $174K | Buy |
+1,188
| New | +$201K | ﹤0.01% | 5526 |
|
Other funds holding CDLX
CIP
6CM
KGAMU
WPM
RC
QOP
Morgan Stanley's CDLX Position: Q2 2026 in Review
Morgan Stanley increased its Cardlytics (CDLX) stake by 4.8% in Q2 2026, buying an estimated $22 and bringing the position to 66 shares worth $297. The position accounts for ﹤0.01% of the portfolio, ranked #7788.
Morgan Stanley first reported a position in CDLX in Q1 2018 and has held it in 34 quarters since. The position peaked at $117M in Q4 2020. 41 funds tracked by Wall St. Rank hold CDLX as of Q2 2026.
- Morgan Stanley held 66 shares of Cardlytics worth $297 as of Q2 2026.
- Morgan Stanley bought 3 Cardlytics shares in Q2 2026, an estimated $22.
- Cardlytics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7788 holding.
- Morgan Stanley first reported a position in Cardlytics in Q1 2018 and has held it in 34 quarters since.
- Morgan Stanley's Cardlytics position peaked at $117M in Q4 2020.
- 41 funds tracked by Wall St. Rank held Cardlytics as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.